MX2022000046A - Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos. - Google Patents

Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos.

Info

Publication number
MX2022000046A
MX2022000046A MX2022000046A MX2022000046A MX2022000046A MX 2022000046 A MX2022000046 A MX 2022000046A MX 2022000046 A MX2022000046 A MX 2022000046A MX 2022000046 A MX2022000046 A MX 2022000046A MX 2022000046 A MX2022000046 A MX 2022000046A
Authority
MX
Mexico
Prior art keywords
tsas
ovarian cancer
hgsc
specific antigens
novel tumor
Prior art date
Application number
MX2022000046A
Other languages
English (en)
Inventor
Pierre Thibault
Sébastien Lemieux
Qingchuan Zhao
Claude Perrault
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal filed Critical Univ Montreal
Publication of MX2022000046A publication Critical patent/MX2022000046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

El cáncer de ovario, en particular, el carcinoma seroso de alto grado (HGSC), la principal causa de muerte por neoplasias ginecológicas en el mundo, no se ha visto beneficiado de manera significativa del progreso reciente en cuanto a la inmunoterapia contra el cáncer; a pesar de que la infiltración de HGSC con linfocitos se correlaciona con la supervivencia superior, la naturaleza de los antígenos que pueden provocar respuestas inmunitarias anti-HGSC es desconocida; en la presente se describen antígenos específicos de tumores (TAS) novedosos compartidos por una gran proporción de tumores de ovario; la mayoría de los TSA (>80%) descritos en la presente se deriva de secuencias genómicas no mutadas expresadas de manera anormal, como las secuencias intrónicas o intergénicas, que no se expresan en tejidos normales; se describen ácidos nucleicos, composiciones, células y vacunas derivados de estos TSA; además, se describe el uso de los TSA, ácidos nucleicos, composiciones, células y vacunas para el tratamiento de cáncer de ovario.
MX2022000046A 2019-06-25 2020-06-22 Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos. MX2022000046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866089P 2019-06-25 2019-06-25
PCT/CA2020/050869 WO2020257922A1 (en) 2019-06-25 2020-06-22 Novel tumor-specific antigens for ovarian cancer and uses thereof

Publications (1)

Publication Number Publication Date
MX2022000046A true MX2022000046A (es) 2022-02-24

Family

ID=74059840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000046A MX2022000046A (es) 2019-06-25 2020-06-22 Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos.

Country Status (12)

Country Link
US (1) US20220354937A1 (es)
EP (1) EP3990483A4 (es)
JP (1) JP2022539301A (es)
KR (1) KR20220025808A (es)
CN (2) CN118666956A (es)
AU (1) AU2020301838A1 (es)
BR (1) BR112021025943A2 (es)
CA (1) CA3141898A1 (es)
IL (1) IL288826A (es)
MX (1) MX2022000046A (es)
SG (1) SG11202113192QA (es)
WO (1) WO2020257922A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019330487A1 (en) 2018-08-30 2021-02-04 Université de Montréal Proteogenomic-based method for identifying tumor-specific antigens
JP2024527620A (ja) * 2021-07-16 2024-07-25 ウニヴェルシテ ド モントリオール がん幹細胞に対する新規の腫瘍特異的抗原及びそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003111595A (ja) * 2001-06-25 2003-04-15 Kyogo Ito 腫瘍抗原
EP3777882A1 (en) * 2013-07-30 2021-02-17 BioNTech SE Tumor antigens for determining cancer therapy
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
CA3141229A1 (en) * 2019-06-28 2020-12-30 The Francis Crick Institute Limited Novel cancer antigens and methods

Also Published As

Publication number Publication date
CN114026117B (zh) 2024-07-05
EP3990483A4 (en) 2024-02-21
WO2020257922A1 (en) 2020-12-30
IL288826A (en) 2022-02-01
CN118666956A (zh) 2024-09-20
CA3141898A1 (en) 2020-12-30
SG11202113192QA (en) 2021-12-30
CN114026117A (zh) 2022-02-08
US20220354937A1 (en) 2022-11-10
BR112021025943A2 (pt) 2022-02-08
EP3990483A1 (en) 2022-05-04
JP2022539301A (ja) 2022-09-08
AU2020301838A1 (en) 2022-02-10
KR20220025808A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2022000046A (es) Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos.
WO2018234506A3 (en) PERSONALIZED VACCINE
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
Qasim et al. Third‐party virus‐specific T cells eradicate adenoviraemia but trigger bystander graft‐versus‐host disease
JP2016531927A5 (es)
WO2021094562A3 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
RU2011110376A (ru) Эпитопные пептиды hig2 и urlc10 и содержание их вакцины
MX2022012758A (es) Novedosos antigenos especificos de tumores para leucemia mieloide aguda (aml) y usos de estos.
Song et al. Development and characterization of 22 polymorphic microsatellite markers for the balloon flower Platycodon grandiflorum (Campanulaceae)
Bubenik Animal models for development of therapeutic HPV16 vaccines
AR081065A1 (es) Peptidos ect2 (secuencia 2 de transformacion de la celula epitelial) y vacunas que los incluyen
Hassan et al. Study of fibromodulin gene expression in B-cell chronic lymphocytic leukemia
MX2024003142A (es) Antigenos especificos de tumores novedosos para el cancer colorrectal y usos de estos.
MX2020011794A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
WO2002068451A3 (en) Sperm protein 17 for the diagnosis and treatment of cancer
Mbaye et al. Genetic diversity of breast cancer in senegalese women: new insight from somatic mutations
FI3335725T3 (fi) Pds5a-epitooppeja immuuniteetin indusoijina
Bosslet et al. Clonal tumor cell variants arising by adaptation
CN103214556B (zh) Mta1来源的抗肿瘤ctl表位肽及其应用
CN116763906A (zh) 一种树突肿瘤疫苗培植技术
CN103204908B (zh) Mta1来源的抗肿瘤ctl表位肽及其应用
JP5279063B2 (ja) Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途
CN103145801B (zh) Mta1来源的抗肿瘤ctl表位肽及其应用
Pulido-Cejudo et al. Gene-editing: Translating bacterial adaptive immunity into promising cancer therapies
Parrella et al. First report of Tomato spotted wilt virus in Iberis semperflorens.